KoDiscovery and New G Lab Pharma

NewGLab Pharma is a South Korean biotechnology company specializing in the development of metabolic anticancer drugs. The company's core technology, KAT (KoDiscovery Anti-cancer Technology), utilizes 3-bromopyruvate to target and inhibit the glycolytic enzymes Hexokinase 2 and Glyceraldehyde-3-phosphate dehydrogenase. This mechanism effectively starves cancer cells of energy by disrupting their primary metabolic pathways. The lead candidate is currently being evaluated in clinical trials for the treatment of hepatocellular carcinoma and other advanced solid tumors. Through its subsidiary KoDiscovery, founded by Dr. Young Hee Ko, the company maintains a research presence in both South Korea and the United States. NewGLab Pharma is listed on the KOSDAQ exchange and continues to expand its oncology pipeline through innovative metabolic modulation strategies.